Department of Surgery, Hospital Clínico Universitario de Valencia, Valencia, Spain.
J Breast Cancer. 2013 Mar;16(1):104-11. doi: 10.4048/jbc.2013.16.1.104. Epub 2013 Mar 31.
The objective of this study was to describe the evolution of health-related quality of life (HRQOL) in a cohort of breast cancer patients over 1 year after surgery and to analyse the predictive ability of HRQOL measurement instruments.
Observational, multicenter and prospective study of a cohort of breast cancer patients, assessing HRQOL at 1, 6, and 12 months after surgery using three questionnaires: EuroQol-5D-3L, EORTC QLQ-C30, and EORTC QLQ-BR23.
A total of 364 women participated in the study. Visual Analogue Scale (VAS) scores from the EuroQol improved (1 month vs. 1 year: 70 vs. 80; p<0.0001); however, the EuroQol score showed no significant change (0.81 vs. 0.83; p=0.1323). In contrast, Global Health Status on the EORTC QLQ-C30 improved (66.67 vs. 100.00; p<0.0001), as did all of this instrument's scales and most of its independent items. The EORTC QLQ-BR23 dimensions showed improvement, except for sexual functioning (100.00 vs. 86.67; p=0.0030) and future perspective (33.33 vs. 66.67; p<0.0001). Patients with good HRQOL outcomes at 1 month showed improved levels of HRQOL at 1 year; HRQOL measured at 1 month was predictive of HRQOL at 1 year.
HRQOL improved during the follow-up period. Likewise, HRQOL measurement instruments can predict early HRQOL.
本研究旨在描述手术后 1 年乳腺癌患者健康相关生活质量(HRQOL)的演变,并分析 HRQOL 测量工具的预测能力。
这是一项观察性、多中心、前瞻性的乳腺癌患者队列研究,使用三个问卷评估术后 1、6 和 12 个月的 HRQOL:EuroQol-5D-3L、EORTC QLQ-C30 和 EORTC QLQ-BR23。
共有 364 名女性参与了这项研究。EuroQol 的视觉模拟量表(VAS)评分有所改善(1 个月 vs. 1 年:70 vs. 80;p<0.0001);然而,EuroQol 评分没有显著变化(0.81 vs. 0.83;p=0.1323)。相比之下,EORTC QLQ-C30 的总体健康状况得到改善(66.67 vs. 100.00;p<0.0001),以及该工具的所有量表和大多数独立项目。EORTC QLQ-BR23 的维度都有所改善,除了性功能(100.00 vs. 86.67;p=0.0030)和未来展望(33.33 vs. 66.67;p<0.0001)。在第 1 个月 HRQOL 结果良好的患者在第 1 年时 HRQOL 水平得到了改善;第 1 个月测量的 HRQOL 可以预测第 1 年的 HRQOL。
在随访期间,HRQOL 得到了改善。同样,HRQOL 测量工具可以预测早期 HRQOL。